Volume 58, Issue 11 pp. 1258-1263
Report

Kaposi sarcoma in Southern Finland (2006–2018)

Nicolas Kluger MD, PhD

Corresponding Author

Nicolas Kluger MD, PhD

Dermatology, Allergology and Venereology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland

Correspondence

Nicolas Kluger, md, phd

Department of Dermatology

Skin and Allergies Hospital

Meilahdentie 2

PO Box 160 00029 HUS

Finland

E-mail: [email protected]

Search for more papers by this author
Carl Blomqvist MD, PhD

Carl Blomqvist MD, PhD

Comprehensive Cancer Center, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland

Search for more papers by this author
Pia Kivelä MD, PhD

Pia Kivelä MD, PhD

Department of Infectious Diseases, Center of Inflammation, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland

Search for more papers by this author
First published: 20 June 2019
Citations: 4
Funding sources: None
Conflict of interest: None

Abstract

Background

Kaposi sarcoma (KS) age-standardized incidence rate is below 0.3 per 100,000 in Nordic countries. Data on KS in Finland have been sparse.

Methods

A retrospective review of all the patients with KS cases managed in the Helsinki University Central Hospital between 2006 and 2018.

Results

Forty patients (median age at diagnosis 45 years, 38 males) were included. About 2.5 new cases were diagnosed per year (incidence 0.16 /100,000). The different subtypes of KS were: human immunodeficiency virus (HIV) (65%), classical KS (30%), and immunodepression (5%). Patients with HIV were significantly younger, more likely to have cutaneous lesions of the face, the trunk, and mucosal lesions, and KS within lymph nodes and inner organs. KS was diagnosed at the same time as HIV in 77% of cases, 28% with CD4-cell level above 300 cells/mm3. Among the patients with classical KS (n = 12), 75% were of Finnish origin, 41% had a second primary malignancy diagnosed, and 25% had noninsulin dependent diabetes mellitus. Among HIV patients, 27% had another AIDS-related illness, 7% of the patients developed lymphoproliferative disorders, and 7% a hemophagocytic syndrome. Patients with HIV were always treated with antiviral therapy, with pegylated liposomal doxorubicin in 57% of the cases. Local radiotherapy was the main treatment for other KS types. None of the 5 deaths during follow-up was related to KS.

Conclusions

Classical KS (KS-CLA) occurs among native Finns, frequently with other present malignancies. Screening of HIV and other malignancies is warranted in new cases of KS.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.